Magnesium Nebulization Utilization in Management of Pediatric Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

818

Participants

Timeline

Start Date

September 26, 2011

Primary Completion Date

November 19, 2019

Study Completion Date

November 22, 2019

Conditions
Acute Asthma
Interventions
DRUG

Magnesium Sulfate Sandoz

Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz

DRUG

Sodium Chloride , USP PPC

Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience

Trial Locations (7)

T3B 6A8

Alberta Children's Hospital, Calgary

T6G1C9

Stollery Hospital, Edmonton

V6H 3V4

BC Children's Hospital, Vancouver

R3E3P4

The Manitoba Institute of Child Health, Winnipeg

K1H8L1

Children's Hospital of Eastern Ontario, Ottawa

M5V1X8

The Hospital for Sick Children, Toronto

H3T1C5

Ste Justine Hospital, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Alberta Children's Hospital

OTHER

collaborator

St. Justine's Hospital

OTHER

collaborator

Children's Hospital of Eastern Ontario

OTHER

collaborator

Stollery Children's Hospital

OTHER

collaborator

The Children's Hospital of Winnipeg

OTHER

collaborator

Provincial Health Services Authority

OTHER

lead

The Hospital for Sick Children

OTHER

NCT01429415 - Magnesium Nebulization Utilization in Management of Pediatric Asthma | Biotech Hunter | Biotech Hunter